The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_000152.5(GAA):c.2417C>T (p.Thr806Met)

CA8815734

252467 (ClinVar)

Gene: GAA
Condition: glycogen storage disease II
Inheritance Mode: Autosomal recessive inheritance
UUID: 41d937cd-df8d-4860-9f35-cf602183e669

HGVS expressions

NM_000152.5:c.2417C>T
NM_000152.5(GAA):c.2417C>T (p.Thr806Met)
NC_000017.11:g.80117685C>T
CM000679.2:g.80117685C>T
NC_000017.10:g.78091484C>T
CM000679.1:g.78091484C>T
NC_000017.9:g.75706079C>T
NG_009822.1:g.21130C>T
ENST00000302262.8:c.2417C>T
ENST00000302262.7:c.2417C>T
ENST00000390015.7:c.2417C>T
ENST00000573556.1:n.370C>T
NM_000152.3:c.2417C>T
NM_001079803.1:c.2417C>T
NM_001079804.1:c.2417C>T
NM_000152.4:c.2417C>T
NM_001079803.2:c.2417C>T
NM_001079804.2:c.2417C>T
NM_001079803.3:c.2417C>T
NM_001079804.3:c.2417C>T

Uncertain Significance

Met criteria codes 1
BP4
Not Met criteria codes 2
BS1 PM2

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Lysosomal Storage Disorders Variant Curation Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 2

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Lysosomal Diseases VCEP
The NM_000152.5: c.2417C>T variant in GAA is a missense variant predicted to cause substitution of threonine by methionine at amino acid 806 (p.Thr806Met). To our knowledge, this variant has not been reported in the literature in individuals with Pompe disease, and the results of experimental studies are not available. The highest population minor allele frequency in gnomAD v2.1.1 is 0.001189 (42/35310 alleles) in Latino/Admixed American population. This allele frequency meets neither the PM2 allele frequency threshold (<0.001) nor the BS1 allele frequency threshold (>0.005) specified by the ClinGen Lysosomal Diseases VCEP. The computational predictor REVEL gives a score of 0.435 which is below the threshold of 0.5, evidence that does not predict a damaging effect on GAA function. No impact on splicing is predicted by SpliceAI (BP4). There is a ClinVar entry for this variant (Variation ID: 252467). In summary, this variant meets the criteria to be classified as a variant of uncertain significance for Pompe disease due to insufficient evidence. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases VCEP (Specifications Version 2.0): BP4. (Classification approved by the ClinGen Lysosomal Diseases VCEP on June 20, 2023).
Met criteria codes
BP4
The computational predictor REVEL gives a score of 0.435 which is below the threshold of 0.5, evidence that does not predict a damaging effect on GAA function. No impact on splicing is predicted by SpliceAI (BP4).
Not Met criteria codes
BS1
The highest population minor allele frequency in gnomAD v2.1.1 is 0.001189 (42/35310 alleles) in Latino/Admixed American population, which is lower than the ClinGen LSD VCEP threshold (>0.005) for BS1, and does not meet this criterion.
PM2
The highest population minor allele frequency in gnomAD v2.1.1 is 0.001189 (42/35310 alleles) in Latino/Admixed American population, which is higher than the ClinGen LSD VCEP threshold (<0.001) for PM2, and does not meet this criterion.
Approved on: 2023-06-20
Published on: 2023-06-26
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.